SG11201502599TA - Non-cross-linked acellular pertussis antigens for use in combination vaccines - Google Patents

Non-cross-linked acellular pertussis antigens for use in combination vaccines

Info

Publication number
SG11201502599TA
SG11201502599TA SG11201502599TA SG11201502599TA SG11201502599TA SG 11201502599T A SG11201502599T A SG 11201502599TA SG 11201502599T A SG11201502599T A SG 11201502599TA SG 11201502599T A SG11201502599T A SG 11201502599TA SG 11201502599T A SG11201502599T A SG 11201502599TA
Authority
SG
Singapore
Prior art keywords
cross
combination vaccines
acellular pertussis
pertussis antigens
linked acellular
Prior art date
Application number
SG11201502599TA
Other languages
English (en)
Inventor
Lorenzo Tarli
Mario Contorni
Alessandro Bartalesi
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of SG11201502599TA publication Critical patent/SG11201502599TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/30011—Nodaviridae
    • C12N2770/30034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SG11201502599TA 2012-10-12 2013-10-11 Non-cross-linked acellular pertussis antigens for use in combination vaccines SG11201502599TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261713356P 2012-10-12 2012-10-12
PCT/EP2013/071372 WO2014057132A1 (en) 2012-10-12 2013-10-11 Non-cross-linked acellular pertussis antigens for use in combination vaccines

Publications (1)

Publication Number Publication Date
SG11201502599TA true SG11201502599TA (en) 2015-05-28

Family

ID=49326692

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201502599TA SG11201502599TA (en) 2012-10-12 2013-10-11 Non-cross-linked acellular pertussis antigens for use in combination vaccines

Country Status (13)

Country Link
US (2) US20150273036A1 (es)
EP (2) EP2906239A1 (es)
JP (1) JP6440619B2 (es)
KR (1) KR20150065878A (es)
CN (1) CN104918634A (es)
AU (1) AU2013328548A1 (es)
BR (1) BR112015008040A2 (es)
CA (1) CA2886938A1 (es)
IL (1) IL238023A0 (es)
MX (3) MX2015004652A (es)
RU (1) RU2015111987A (es)
SG (1) SG11201502599TA (es)
WO (1) WO2014057132A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
EP3283102A4 (en) * 2015-04-16 2018-10-03 Inventprise, LLC. Bordetella pertussis immunogenic vaccine compositions
KR102405736B1 (ko) * 2016-01-15 2022-06-07 케이엠 바이올로직스 가부시키가이샤 고정화 바이러스 입자를 포함하는 백신
KR102362777B1 (ko) * 2018-03-27 2022-02-15 주식회사 녹십자 친화성 크로마토그래피 공정을 포함하는 백일해균 유래 단백질 수득 방법
EP4327820A1 (en) * 2021-04-20 2024-02-28 KM Biologics Co., Ltd. Liquid sextuple vaccine composition

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
DE3485094D1 (de) 1983-01-25 1991-10-31 Ciba Geigy Ag Neue peptidderivate.
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4624918A (en) 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
IT1223334B (it) * 1987-11-02 1990-09-19 Sclavo Spa Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse
GB8727489D0 (en) * 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
ES2078258T3 (es) 1989-04-28 1995-12-16 Sclavo Spa Mutantes de toxina pertussica, cepas de bordetella capaces de producir tales mutantes y su uso en el desarrollo de vacunas antipertussicas.
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
SK280702B6 (sk) 1992-05-23 2000-06-12 Smithkline Beecham Biologicals S. A. Kombinovaný očkovací prostriedok obsahujúci povrch
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
GB9216351D0 (en) 1992-07-31 1992-09-16 Wellcome Found Vaccine production
DK0812593T4 (da) 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
DE122009000058I1 (de) 1993-09-22 2009-12-31 Jackson H M Found Military Med Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
WO1996040242A1 (en) 1995-06-07 1996-12-19 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein
ATE433329T1 (de) 1995-06-23 2009-06-15 Glaxosmithkline Biolog Sa Impfstoff bestehend aus auf aluminium-phosphat adsorbiertem, konjugiertem polysaccharid antigen
AU714493B2 (en) * 1996-07-02 2000-01-06 Connaught Laboratories Limited Multivalent DTP-polio vaccines
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
AU4707097A (en) * 1997-09-15 1999-04-05 Pasteur Merieux Serums Et Vaccins Multivalent vaccines
PT1075276E (pt) 1998-05-07 2008-01-22 Corixa Corp Composição adjuvante e métodos para sua utilização
DE69941574D1 (de) 1998-08-19 2009-12-03 Baxter Healthcare Sa Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
HU228499B1 (en) 1999-03-19 2013-03-28 Smithkline Beecham Biolog Streptococcus vaccine
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
UA85853C2 (uk) 2000-06-29 2009-03-10 Глаксосмітклайн Байолоджікалз С.А. Полівалентна імуногенна композиція
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0202901D0 (en) 2002-02-07 2002-03-27 Glaxosmithkline Biolog Sa Novel vaccine
WO2004041157A2 (en) 2002-09-13 2004-05-21 Chiron Corporation Group b streptococcus vaccine
KR20090051129A (ko) 2004-04-05 2009-05-20 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
SI1740217T1 (sl) * 2004-04-30 2011-10-28 Novartis Ag Konjugirano meningokokno cepljenje
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
AR056591A1 (es) 2005-10-28 2007-10-10 Vaxinnate Corp Polipeptidos ligandos para receptor 4 simil toll (tlr4)
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
AU2006327023A1 (en) * 2005-12-23 2007-06-28 Glaxosmithkline Biologicals Sa Conjugate vaccines
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
PL2038290T3 (pl) 2006-07-07 2014-03-31 Gilead Sciences Inc Modulatory receptora Toll-podobnego 7
NZ575273A (en) 2006-09-07 2012-02-24 Glaxosmithkline Biolog Sa Method for making combination vaccine comprising inactivated poliovirus type 1, diptheria toxoid and tetanus toxoid
PT2086582E (pt) 2006-10-12 2013-01-25 Glaxosmithkline Biolog Sa Vacina compreendendo uma emulsão adjuvante óleo em água
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
US20100074918A1 (en) * 2007-05-02 2010-03-25 Jan Poolman Vaccine
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
US8092813B1 (en) 2007-12-28 2012-01-10 Novartis Ag Polychlorinated biphenyls and squalene-containing adjuvants
SI2268618T1 (sl) 2008-03-03 2015-09-30 Novartis Ag Spojine in sestavki kot modulatorji aktivnosti TLR
EA029926B1 (ru) 2008-03-24 2018-05-31 4ЭсЦэ АГ 1,2-дизамещенные 4-амино-имидазохинолины, содержащая их фармацевтическая композиция и их применение в качестве активаторов toll-подобных рецепторов 7 (варианты)
JP5600104B2 (ja) 2008-08-01 2014-10-01 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッド Ｔｏｌｌ様受容体アゴニスト処方物およびその使用
WO2010023551A2 (en) 2008-08-28 2010-03-04 Michael Broeker Production of squalene from hyper-producing yeasts
CN102762226A (zh) 2009-06-10 2012-10-31 诺华有限公司 含苯并萘啶的疫苗
CN102753149B (zh) 2009-12-03 2015-10-14 诺华股份有限公司 乳液微流化和/或均化期间的组分循环
DK2343052T3 (da) 2009-12-03 2013-09-02 Novartis Ag Hydrofil filtrering under fremstilling af vaccineadjuvanter
SI2506833T1 (sl) 2009-12-03 2014-07-31 Novartis Ag Sklop interakcijske in protitlaäśne komore za mikrofluidiziranje
WO2011141819A1 (en) 2010-05-12 2011-11-17 Novartis Ag Improved methods for preparing squalene
GB201009671D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009673D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009676D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
US20120177681A1 (en) 2010-09-01 2012-07-12 Manmohan Singh Formulation of immunopotentiators

Also Published As

Publication number Publication date
US20150273036A1 (en) 2015-10-01
BR112015008040A2 (pt) 2017-07-04
US20200138927A1 (en) 2020-05-07
MX2015004652A (es) 2015-08-05
CA2886938A1 (en) 2014-04-17
WO2014057132A1 (en) 2014-04-17
JP2015533148A (ja) 2015-11-19
JP6440619B2 (ja) 2018-12-19
EP2906239A1 (en) 2015-08-19
KR20150065878A (ko) 2015-06-15
IL238023A0 (en) 2015-05-31
MX2019013641A (es) 2020-01-21
RU2015111987A (ru) 2016-12-10
AU2013328548A1 (en) 2015-05-07
CN104918634A (zh) 2015-09-16
EP3620172A1 (en) 2020-03-11
MX2019002024A (es) 2019-07-22

Similar Documents

Publication Publication Date Title
HK1207962A1 (en) Mycobacterial antigen vaccine
ZA201308461B (en) Multiple antigen presenting immunogenic composition and methods and uses thereof
EP2714073A4 (en) ANTI-CANCER ANTIGEN GENE VACCINE IN SITU
HK1199711A1 (en) Bioconjugate vaccines made in prokaryotic cells
ZA201404712B (en) Composite antigenic sequences and vaccines
EP2825196A4 (en) ADJUVANT AND VACCINE COMPOSITIONS
IL241271A0 (en) Pertussis vaccine
HK1206970A1 (en) Antigenic compositions and methods
IL234604A (en) Carbon-glycophide vaccines are vaccinated
IL238023A0 (en) Uncrosslinked pertussis antigens for use in combination formulations
IL229956B (en) 1mphosph peptides and ingredients containing them
IL242584B (en) An immunogenic preparation for use in treatment
EP2771453A4 (en) DIATOM-BASED VACCINES
SG11201505086QA (en) Immunogenic composition comprising mycoplasma antigens
ZA201306245B (en) Combination vaccines
EP2872532A4 (en) CDCA1-EPITOPPEPTIDES FOR TH1 CELLS AND VACCINES THEREWITH
PL2591798T3 (pl) Szczepionka do zastosowania w immunoterapii nowotworów
EP2929894A4 (en) VACCINE ADJUVANS, PREPARATION AND VACCINES THEREOF
EP2872531A4 (en) LY6K EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME
HK1198940A1 (en) Vaccines for human papilloma virus and methods for using the same
ZA201504231B (en) Leptospira with increased antigenic mass
ZA201506581B (en) Acellular pertussis vaccine
ZA201508585B (en) Immunogenic composition for use in therapy
IL228649B (en) Immunogenic preparations for use in treatment
ZA201307648B (en) Antigenic formulation